TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04659447
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
Study: NCT00457093
Drug: glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00457093
Drug: detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02095444
Drug: Menstrual blood stem cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10\*7 cells/kg, intravenous injection for 4 times during two weeks
Study: NCT03109418
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Study: NCT01597934
Drug: Group A (Zeffix, Sebivo, Hepsera)
Normalized name: meningococcal group A polysaccharide
DrugBank: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (DB10798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
Study: NCT01597934
Drug: Group B (Baraclude, Viread)
Normalized name: meningococcal group B vaccine
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
Study: NCT01054339
Drug: rAAV1-CB-hAAT
Normalized name: rAAV1-CB-hAAT
DrugBank: rAAV1-CB-hAAT (DB18724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
Study: NCT00722410
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of 3 liters of polyethylene glycol solution.
Study: NCT00461851
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Study: NCT00461851
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given on day 1 to an AUC of 5.
Study: NCT00461851
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
Study: NCT00699361
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 160 mg I.V.
Study: NCT00699361
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 160 mg intravenously (IV)
Study: NCT02340936
Drug: LR-ESHAP (lenalidomide 5 mg)
Normalized name: lenalidomide 5 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT02340936
Drug: LR-ESHAP (lenalidomide 10 mg)
Normalized name: lenalidomide 10 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT02340936
Drug: LR-ESHAP (lenalidomide 15 mg)
Normalized name: lenalidomide 15 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT02340936
Drug: LR-ESHAP (lenalidomide 20 mg)
Normalized name: lenalidomide 20 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study: NCT02798172
Drug: Alogliptin and Metformin
Normalized name: Alogliptin and metformin only product
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
Study: NCT03260881
Drug: Liraglutide Pen Injector [Victoza]
Normalized name: liraglutide Pen Injector [Victoza]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Study: NCT03260881
Drug: matching liraglutide-placebo pre-filled pens
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
Study: NCT04360889
Drug: Tocopherol
Normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
Study: NCT01572844
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
Study: NCT03776864
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00983944
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00983944
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or orally
Study: NCT00983944
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or orally
Study: NCT03243851
Drug: Temozolomide+Metformin
Normalized name: Temozolomide
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low dose temozolomide+metformin for 24 weeks
Study: NCT03243851
Drug: Temozolomide+Placebo
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose temozolomide+placebo for 24 weeks
Study: NCT02571712
Drug: bimatoprost 0.03% plus timolol 0.5%
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
Study: NCT01448317
Drug: Alirocumab (Solution)
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02056743
Drug: Fexofenadine 30mg
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each group administered Fexofenadine 30mg under fasting conditions.
Study: NCT02913703
Drug: Ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
Study: NCT03388346
Drug: Ga-68 PSMA-HBED-CC PET
Normalized name: Psma-hbed-CC Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Study: NCT00330577
Drug: timolol maleate 0.5%
Normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00497939
Drug: Saw palmetto and sanmiaoshan capsule
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00898950
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 75mgs/day orally for 2 weeks.
Study: NCT00898950
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mgs/day orally for 2 weeks
Study: NCT00898950
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 900mgs QID orally for 2 weeks
Study: NCT00330577
Drug: latanoprost/timolol fixed combination
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00940524
Drug: Dasatinib, Mitoxantrone, Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29
Study: NCT00075634
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01813630
Drug: DA-3002
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01462422
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
Study: NCT01462422
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
Study: NCT03479203
Drug: Electronic Cigarette Aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 two-second-long puffs from a non-nicotinized electronic cigarette.
Study: NCT04509635
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is used for only patients with ctDNA test RAS wild type.
Study: NCT03922919
Drug: Cefotaxime Injection
Normalized name: cefotaxime Injection
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systematic use of cefotaxime.
Study: NCT03922919
Drug: Cefotaxime/ceftriaxone
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
Study: NCT02362256
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02362256
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02362256
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02134912
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04177706
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
Study: NCT01228669
Drug: NNC 0172-0000-2021
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
Study: NCT01228669
Drug: NNC 0172-0000-2021
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
Study: NCT02646358
Drug: Vepoloxamer
Normalized name: Vepoloxamer
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03065569
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 mL of 0.125% bupivacaine
Study: NCT02134912
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04715958
Drug: Perflutren Lipid Microspheres
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00184366
Drug: efalizumab
Normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: efalizumab
Study: NCT03710460
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg, one per day before breakfast during 12 weeks.
Study: NCT03710460
Drug: Dapagliflozin plus Metformin XR
Normalized name: dapagliflozin / metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10/1000 mg, one per day before breakfast during 12 weeks.
Study: NCT03710460
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg, one per day before breakfast during 12 weeks.
Study: NCT00443794
Drug: Ramipril with Thiazide
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule (blinded) oral administration 12 weeks
Study: NCT00443794
Drug: Thiazide plus atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caspule (blinded) for oral administration once daily for 12 weeks
Study: NCT00443794
Drug: Ramipril plus atenolol
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule ( blinded) for oral administration once daily for 12 weeks
Study: NCT00443794
Drug: Ramipril plus atenolol plus thiazide
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule (blinded) for oral administration once daily for 12 weeeks
Study: NCT00443794
Drug: POLYCAP
Normalized name: Atriplex polycarpa pollen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for Oral Administration once daily for 12 weeks
Study: NCT00443794
Drug: Thiazide + Ramipril+Atenolol+Aspirin
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule (Blinded) for oral administration once daily for 12 weeks
Study: NCT00443794
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule (Blinded) for oral administration once daily for 12 weeks
Study: NCT00772980
Drug: Neramexane mesylate
Normalized name: mesylate
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
Study: NCT00103935
Drug: Exenatide LAR
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
Study: NCT00103935
Drug: Exenatide LAR
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
Study: NCT00025090
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00025090
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00979004
Drug: ICA-105665
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
Study: NCT00370825
Drug: Combination therapy with AmBisome and miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00303329
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Study: NCT00025610
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025610
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025610
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00574834
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 20 mg once daily for 6 months
Study: NCT00574834
Drug: Ramipril+HCTZ
Normalized name: hydrochlorothiazide / ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
Study: NCT00713609
Drug: Benzoyl peroxide gel
Normalized name: Benzoyl Peroxide Gel
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% benzoyl peroxide in a gel applied topically once a day
Study: NCT00713609
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 % tazarotene in a cream applied topically once a day
Study: NCT00060528
Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
Normalized name: RECOMBINANT STABILIZED RSV A PREFUSION F ANTIGEN
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060528
Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)
Normalized name: vaccinia virus
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00794235
Drug: Sorafenib (Nexavar), Dacarbazine (DTIC)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42.
Study: NCT04354870
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
Study: NCT01697059
Drug: Piperacillin + Amoxicillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01964534
Drug: ABI-007
Normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Study: NCT01964534
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² IV /30min (day 1, day 8, day 15)
Study: NCT00050440
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
Study: NCT00050440
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
Study: NCT03040479
Drug: lasmiditan 200 mg
Normalized name: lasmiditan 200 MG
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose
Study: NCT02005549
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
Study: NCT02005549
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
Study: NCT01964534
Drug: simplified LV5FU2
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
Study: NCT01057433
Drug: Pitavastatin (NK-104)
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pitavastatin (NK-104) 4 mg once daily (QD)
Study: NCT01057433
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir 800 mg/200 mg
Study: NCT00134199
Drug: sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00210067
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
DrugBank: Denufosol (DB04983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00426829
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
Study: NCT03283371
Drug: Natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As specified in the treatment arm.
Study: NCT04945499
Drug: d-glucose
Normalized name: D-glucose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: using d-glucose as an contrast agent on CEST MR Imaging
Study: NCT01747707
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01747707
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no